Key Takeaways Interventional Urology growth is due to UroLift expansion in Japan, China, and new U.S. system launches. Barrigel is gaining traction in the U.S. and Japan, supported by favorable safety and efficacy trial data. TFX faces pressure from a highly leveraged balance sheet and adverse FX impacts on global revenues. Teleflex’s (TFX) Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by f ...